Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - risperidone - tablets - risperidone 3 mg - risperidone - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - risperidone - caplets - risperidone 4 mg - risperidone - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

dexcel pharma gmbh carl-zeiss-str. 2 63755 alzenau (duitsland) - verapamilhydrochloride 240 mg/stuk samenstelling overeenkomend met ; verapamil 222,2 mg/stuk - tablet met gereguleerde afgifte - carnaubawas (e 903) ; cellulose, microkristallijn (e 460(i)) ; chinolinegeel (e 104) ; hypromellose (release controlling polymer)(e 464) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; indigokarmijn (e 132) ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumalginaat (e 401) ; povidon (e 1201) ; siliciumdioxide (e 551) ; titaandioxide (e 171), carnaubawas (e 903) ; cellulose, microkristallijn (e 460) ; chinolinegeel (e 104) ; hypromellose (release controlling polymer)(e 464) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; indigokarmijn (e 132) ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumalginaat (e 401) ; povidon (e 1201) ; siliciumdioxide (e 551) ; titaandioxide (e 171), - verapamil

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

dexcel pharma ltd - atorvastatine - comprimé - 40 mg - composition pour un comprimé > atorvastatine : 40 mg . sous forme de : atorvastatine calcique hémihydratée - agents modifiants les lipides, inhibiteurs de la hmg‑coa réductase

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

dexcel pharma ltd - atorvastatine - comprimé - 20 mg - composition pour un comprimé > atorvastatine : 20 mg . sous forme de : atorvastatine calcique hémihydratée - agents modifiants les lipides, inhibiteurs de la hmg‑coa réductase

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

dexcel pharma ltd - atorvastatine - comprimé - 10 mg - composition pour un comprimé > atorvastatine : 10 mg . sous forme de : atorvastatine calcique hémihydratée - agents modifiants les lipides, inhibiteurs de la hmg‑coa réductase

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

dexcel pharma ltd - irbésartan - comprimé - 300 mg - composition pour un comprimé > irbésartan : 300 mg - antagonistes des récepteurs de l'angiotensine-ii

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

dexcel pharma ltd - irbésartan - comprimé - 75 mg - composition pour un comprimé > irbésartan : 75 mg - antagonistes des récepteurs de l'angiotensine-ii

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

dexcel pharma ltd - irbésartan - comprimé - 150 mg - composition pour un comprimé > irbésartan : 150 mg - antagonistes des récepteurs de l'angiotensine-ii

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

dexcel pharma ltd - valsartan - comprimé - 160 mg - composition pour un comprimé > valsartan : 160 mg - antagonistes de l’angiotensine ii, non associés.